ArticleEndocrinology2015
Central Fibroblast Growth Factor 21 Browns White Fat via Sympathetic Action in Male Mice.
Open access · bronzeAbstract read
In one paragraph
Article in Endocrinology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 120 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
120citing papers in PubMed, 2 pooled it
12.1field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
120 citing papers in PubMed, 2 syntheses or guidelines pooled it, 206 citations in OpenAlex.
- Liver Brain Interactions: Focus on FGF21 a Systematic Review.International journal of molecular sciences · 2022Pooled it
- KLB is associated with alcohol drinking, and its gene product β-Klotho is necessary for FGF21 regulation of alcohol preference.Proceedings of the National Academy of Sciences of the United States of America · 2016Pooled it
- Beneficial effects of Huanglian Jiedu decoction ( ) on metabolic syndrome: a prospective randomized controlled clinical trial.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2026Trial
- FGF21 contributes to metabolic improvements elicited by combination therapy with exenatide and pioglitazone in patients with type 2 diabetes.American journal of physiology. Endocrinology and metabolism · 2022Trial
- The Hormone FGF21 Stimulates Water Drinking in Response to Ketogenic Diet and Alcohol.Cell metabolism · 2018Trial
- Drug Development for MASH-Related Compensated Cirrhosis: Past, Present and Future.Liver international : official journal of the International Association for the Study of the Liver · 2026Review
- Hypothalamus-liver talks: whispers in the language of metabolism.Reviews in endocrine & metabolic disorders · 2026Review
- TOX3 in hypothalamic POMC-lineage cells regulates energy balance via the PTEN-AKT signaling axis.Nature communications · 2026Article
- FGF21 signals through hindbrain neurons to alter food intake and energy expenditure during dietary protein restriction.Cell reports · 2026Article
- A nutrient-hormone axis pivots an energy trade-off between resting thermogenesis and movement expenditure.Journal of sport and health science · 2026Article
- Cross-Talk Between Signaling and Transcriptional Networks Regulating Thermogenesis-Insights into Canonical and Non-Canonical Regulatory Pathways.International journal of molecular sciences · 2026Review
- IUPHAR review: From foe to friend: Repurposing glucagon to treat obesity and type 2 diabetes.Pharmacological research · 2026Review
- Article
- FGF21 acting on the noradrenergic nervous system protects against influenza virus infection.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- GLP-1R/GCGR dual agonism dissipates hepatic steatosis to restore insulin sensitivity and rescue pancreatic β-cell function in obese male mice.Nature communications · 2025Article
- The Possible Role of Metformin and Fibroblast Growth Factor-21 in Multiple Sclerosis Neuropathology: Birds of a Feather Flock Together.The European journal of neuroscience · 2025Review
- Insulin-sensitizing effects of fibroblast growth factor-21 in underfed sheep.Journal of animal science · 2025Article
- [Non-classical hormones from the fibroblast growth factor family].Problemy endokrinologii · 2024Review
- FGF21 mediating the Sex-dependent Response to Dietary Macronutrients.The Journal of clinical endocrinology and metabolism · 2024Review
- ATF4 expression in thermogenic adipocytes is required for cold-induced thermogenesis in mice via FGF21-independent mechanisms.Scientific reports · 2024Article
60 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 2 countries.
Nicholas DourisDivision of Endocrinology (N.D., D.M.S., f.M.F., T.I.C., M.J.C., J.S.F., E.M.-F.), Beth Israel Deaconess Medical Center, Department of Medicine, Harvard Medical School, Boston, Massachusetts 02215-5491; Institute of Medical Physiology (D.M.S.), School of Medicine, University of Belgrade, 11000 Belgrade, Serbia; Department of Biology and Center for Obesity Reversal (N.L.N., E.Z., T.J.B.), Georgia State University, Atlanta, Georgia 30302-4010; and Diabetes Research (A.C.A., A.K.), Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana 46285-0001.
Darko M StevanovicDivision of Endocrinology (N.D., D.M.S., f.M.F., T.I.C., M.J.C., J.S.F., E.M.-F.), Beth Israel Deaconess Medical Center, Department of Medicine, Harvard Medical School, Boston, Massachusetts 02215-5491; Institute of Medical Physiology (D.M.S.), School of Medicine, University of Belgrade, 11000 Belgrade, Serbia; Department of Biology and Center for Obesity Reversal (N.L.N., E.Z., T.J.B.), Georgia State University, Atlanta, Georgia 30302-4010; and Diabetes Research (A.C.A., A.K.), Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana 46285-0001.
Ffolliott M FisherDivision of Endocrinology (N.D., D.M.S., f.M.F., T.I.C., M.J.C., J.S.F., E.M.-F.), Beth Israel Deaconess Medical Center, Department of Medicine, Harvard Medical School, Boston, Massachusetts 02215-5491; Institute of Medical Physiology (D.M.S.), School of Medicine, University of Belgrade, 11000 Belgrade, Serbia; Department of Biology and Center for Obesity Reversal (N.L.N., E.Z., T.J.B.), Georgia State University, Atlanta, Georgia 30302-4010; and Diabetes Research (A.C.A., A.K.), Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana 46285-0001.
Theodore I CisuDivision of Endocrinology (N.D., D.M.S., f.M.F., T.I.C., M.J.C., J.S.F., E.M.-F.), Beth Israel Deaconess Medical Center, Department of Medicine, Harvard Medical School, Boston, Massachusetts 02215-5491; Institute of Medical Physiology (D.M.S.), School of Medicine, University of Belgrade, 11000 Belgrade, Serbia; Department of Biology and Center for Obesity Reversal (N.L.N., E.Z., T.J.B.), Georgia State University, Atlanta, Georgia 30302-4010; and Diabetes Research (A.C.A., A.K.), Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana 46285-0001.
Melissa J CheeDivision of Endocrinology (N.D., D.M.S., f.M.F., T.I.C., M.J.C., J.S.F., E.M.-F.), Beth Israel Deaconess Medical Center, Department of Medicine, Harvard Medical School, Boston, Massachusetts 02215-5491; Institute of Medical Physiology (D.M.S.), School of Medicine, University of Belgrade, 11000 Belgrade, Serbia; Department of Biology and Center for Obesity Reversal (N.L.N., E.Z., T.J.B.), Georgia State University, Atlanta, Georgia 30302-4010; and Diabetes Research (A.C.A., A.K.), Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana 46285-0001.
Ngoc L NguyenDivision of Endocrinology (N.D., D.M.S., f.M.F., T.I.C., M.J.C., J.S.F., E.M.-F.), Beth Israel Deaconess Medical Center, Department of Medicine, Harvard Medical School, Boston, Massachusetts 02215-5491; Institute of Medical Physiology (D.M.S.), School of Medicine, University of Belgrade, 11000 Belgrade, Serbia; Department of Biology and Center for Obesity Reversal (N.L.N., E.Z., T.J.B.), Georgia State University, Atlanta, Georgia 30302-4010; and Diabetes Research (A.C.A., A.K.), Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana 46285-0001.
Eleen ZarebidakiDivision of Endocrinology (N.D., D.M.S., f.M.F., T.I.C., M.J.C., J.S.F., E.M.-F.), Beth Israel Deaconess Medical Center, Department of Medicine, Harvard Medical School, Boston, Massachusetts 02215-5491; Institute of Medical Physiology (D.M.S.), School of Medicine, University of Belgrade, 11000 Belgrade, Serbia; Department of Biology and Center for Obesity Reversal (N.L.N., E.Z., T.J.B.), Georgia State University, Atlanta, Georgia 30302-4010; and Diabetes Research (A.C.A., A.K.), Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana 46285-0001.
Andrew C AdamsDivision of Endocrinology (N.D., D.M.S., f.M.F., T.I.C., M.J.C., J.S.F., E.M.-F.), Beth Israel Deaconess Medical Center, Department of Medicine, Harvard Medical School, Boston, Massachusetts 02215-5491; Institute of Medical Physiology (D.M.S.), School of Medicine, University of Belgrade, 11000 Belgrade, Serbia; Department of Biology and Center for Obesity Reversal (N.L.N., E.Z., T.J.B.), Georgia State University, Atlanta, Georgia 30302-4010; and Diabetes Research (A.C.A., A.K.), Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana 46285-0001.
Alexei KharitonenkovDivision of Endocrinology (N.D., D.M.S., f.M.F., T.I.C., M.J.C., J.S.F., E.M.-F.), Beth Israel Deaconess Medical Center, Department of Medicine, Harvard Medical School, Boston, Massachusetts 02215-5491; Institute of Medical Physiology (D.M.S.), School of Medicine, University of Belgrade, 11000 Belgrade, Serbia; Department of Biology and Center for Obesity Reversal (N.L.N., E.Z., T.J.B.), Georgia State University, Atlanta, Georgia 30302-4010; and Diabetes Research (A.C.A., A.K.), Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana 46285-0001.
Jeffrey S FlierDivision of Endocrinology (N.D., D.M.S., f.M.F., T.I.C., M.J.C., J.S.F., E.M.-F.), Beth Israel Deaconess Medical Center, Department of Medicine, Harvard Medical School, Boston, Massachusetts 02215-5491; Institute of Medical Physiology (D.M.S.), School of Medicine, University of Belgrade, 11000 Belgrade, Serbia; Department of Biology and Center for Obesity Reversal (N.L.N., E.Z., T.J.B.), Georgia State University, Atlanta, Georgia 30302-4010; and Diabetes Research (A.C.A., A.K.), Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana 46285-0001.
Timothy J BartnessDivision of Endocrinology (N.D., D.M.S., f.M.F., T.I.C., M.J.C., J.S.F., E.M.-F.), Beth Israel Deaconess Medical Center, Department of Medicine, Harvard Medical School, Boston, Massachusetts 02215-5491; Institute of Medical Physiology (D.M.S.), School of Medicine, University of Belgrade, 11000 Belgrade, Serbia; Department of Biology and Center for Obesity Reversal (N.L.N., E.Z., T.J.B.), Georgia State University, Atlanta, Georgia 30302-4010; and Diabetes Research (A.C.A., A.K.), Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana 46285-0001.
Eleftheria Maratos-FlierDivision of Endocrinology (N.D., D.M.S., f.M.F., T.I.C., M.J.C., J.S.F., E.M.-F.), Beth Israel Deaconess Medical Center, Department of Medicine, Harvard Medical School, Boston, Massachusetts 02215-5491; Institute of Medical Physiology (D.M.S.), School of Medicine, University of Belgrade, 11000 Belgrade, Serbia; Department of Biology and Center for Obesity Reversal (N.L.N., E.Z., T.J.B.), Georgia State University, Atlanta, Georgia 30302-4010; and Diabetes Research (A.C.A., A.K.), Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana 46285-0001.
Harvard University · USBeth Israel Deaconess Medical Center · USGeorgia State University · USEli Lilly (United States) · US
Funding
Metabolic Actions of FGF21R01DK028082 · NIDDK · BETH ISRAEL DEACONESS MEDICAL CENTER · PI FLIER, JEFFREY S · 1987 to 2018
$5.0MPHOTOPERIODIC CONTROL OF OBESITYR01DK035254 · NIDDK · WORCESTER FOUNDATION FOR BIOMEDICAL RES · PI XUE, BINGZHONG · 1988 to 2015
$3.3MPhotoperiodic Control of ObesityR37DK035254 · NIDDK · GEORGIA STATE UNIVERSITY · PI BARTNESS, TIMOTHY JON · 2009 to 2014
$2.9MPeptidergic Control of Appetitive Ingestive BehaviorsR01DK078358 · NIDDK · GEORGIA STATE UNIVERSITY · PI XUE, BINGZHONG · 2007 to 2016
$2.5MNIDDK NIH HHS 5T32DK751627NIDDK NIH HHS R01 DK028082NIDDK NIH HHS R01 DK035254NIDDK NIH HHS R01 DK078358NIDDK NIH HHS R37 DK035254NIDDK NIH HHS R37 DK35254
Abstract
Fibroblast growth factor 21 (FGF21) has multiple metabolic actions, including the induction of browning in white adipose tissue. Although FGF21 stimulated browning results from a direct interaction between FGF21 and the adipocyte, browning is typically associated with activation of the sympathetic nervous system through cold exposure. We tested the hypothesis that FGF21 can act via the brain, to increase sympathetic activity and induce browning, independent of cell-autonomous actions. We administered FGF21 into the central nervous system via lateral ventricle infusion into male mice and found that the central treatment increased norepinephrine turnover in target tissues that include the inguinal white adipose tissue and brown adipose tissue. Central FGF21 stimulated browning as assessed by histology, expression of uncoupling protein 1, and the induction of gene expression associated with browning. These effects were markedly attenuated when mice were treated with a β-blocker. Additionally, neither centrally nor peripherally administered FGF21 initiated browning in mice lacking β-adrenoceptors, demonstrating that an intact adrenergic system is necessary for FGF21 action. These data indicate that FGF21 can signal in the brain to activate the sympathetic nervous system and induce adipose tissue thermogenesis.
Indexed as
Adipocytes, BrownAdipocytes, WhiteAdipose Tissue, BrownAdipose Tissue, WhiteAdrenergic beta-AntagonistsAnimalsFibroblast Growth FactorsInfusions, IntraventricularIon ChannelsMaleMiceMice, KnockoutMitochondrial ProteinsReceptors, Adrenergic, betaReceptors, Adrenergic, beta-1Receptors, Adrenergic, beta-2Adrenergic beta-Antagonistsfibroblast growth factor 21Fibroblast Growth FactorsIon ChannelsMitochondrial ProteinsReceptors, Adrenergic, betaReceptors, Adrenergic, beta-1Receptors, Adrenergic, beta-2Receptors, Adrenergic, beta-3Ucp1 protein, mouseUncoupling Protein 1
Identifiers
What Socratic holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.